Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | YAP1 | P46937 | 3/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30032767 | 1.00 | GPR119 (0.46) | GPR119YAP1PRMT5STSGHSR | |
| SCHEMBL30031402 | 0.84 | GPR119 (0.41) | GPR119 | |
| SCHEMBL23783127 | 0.84 | GPR119 (0.41) | GPR119 | |
| SCHEMBL8221363 | 0.84 | GPR119 (0.53) | GPR119YAP1CA12CA1CA2 | |
| SCHEMBL30032071 | 0.83 | CCNT1 (0.38) | GPR119YAP1PRMT5STS | |
| SCHEMBL23783137 | 0.83 | CCNT1 (0.38) | GPR119YAP1PRMT5STS | |
| SCHEMBL23783305 | 0.82 | TLR9 (0.37) | GPR119YAP1PRMT5STSGRM5 | |
| SCHEMBL30031986 | 0.82 | TLR9 (0.37) | GPR119YAP1PRMT5STSGRM5 | |
| SCHEMBL23783227 | 0.82 | GPR119 (0.42) | GPR119 | |
| SCHEMBL29554597 | 0.82 | GPR119 (0.42) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-115279370-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | GPR119 2909/4885YAP1 1191/4885PRMT5 2344/4885 |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | GPR119 2909/4885YAP1 1191/4885PRMT5 2344/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | GPR119 2909/4885YAP1 1191/4885PRMT5 2344/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | GPR119 2909/4885YAP1 1191/4885PRMT5 2344/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | GPR119 2909/4885YAP1 1191/4885PRMT5 2344/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | GPR119 2909/4885YAP1 1191/4885PRMT5 2344/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | GPR119 3145/4885YAP1 1955/4885PRMT5 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.